Santen, Clearside Biomedical collaborate on glaucoma; Lipocine completes trials of its oral testosterone;

> Santen Pharmaceuticals and Clearside Biomedical are collaborating on developing glaucoma research. The use of Clearside's proprietary microinjector to deliver sustained intraocular pressure-lowering medications will be studied. More

> Lipocine announced that it has completed the Phase III study of its oral testosterone candidate. "Completion of the last patient visit has Lipocine positioned well to file our New Drug Application with the Food and Drug Administration in line with our previous guidance," said Dr. Mahesh Patel, Chairman, President and CEO of Lipocine, adding, "We are pleased to report that no drug or cardiac related adverse events were observed during this one year study and look forward to sharing top-line results from this safety portion of the study." More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.